BCMA-targeted in vivo lentiviral vector
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for BCMA-targeted in vivo lentiviral vector, covering 2026-01-14 to 2026-01-14. Get the full timeline:
Most recent: Clinical Trial Update: the Safety and Efficacy of Targeted BCMA In Vivo LV Injection for Recurrent or Refractory Autoimmune Diseases [EARLY_Phase 1]